The startup develops proprietary oncology drugs, including humanized antibodies, tailored to treat aggressive tumor phenotypes through a personalized healthcare approach. Their clinical candidate has shown efficacy in multiple tumor models, providing targeted treatment options that enhance recovery for cancer patients.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many aggressive cancers express the L1 cell adhesion molecule (L1CAM), which promotes tumor proliferation, metastasis, angiogenesis, and resistance to chemotherapy. These L1CAM-positive tumors exhibit a highly malignant phenotype, leading to poor patient prognosis.
Solution
Elthera is developing L1CAM-targeted immunotherapies designed to eliminate cancer cells and halt tumor progression by harnessing the patient’s own immune system. The therapeutic molecules simultaneously bind to L1CAM on tumor cells and specific receptors on immune cells, activating the immune cells' lytic functions. This approach recruits immune cells to the tumor, facilitating tumor cell destruction and fostering an immune response against the cancer. Elthera has an exclusive worldwide license to intellectual property rights for the development and commercialization of anti-L1CAM antibodies.
Target Audience
The primary target audience includes patients with aggressive malignancies expressing L1CAM, as well as oncologists and researchers focused on developing novel immunotherapeutic strategies.
Features
- Targets L1CAM, a cell surface protein aberrantly expressed in various aggressive tumor types
- Employs a dual-binding mechanism, targeting both L1CAM on tumor cells and activating receptors on immune cells
- Designed to promote the development of a sustained immune response against cancer
- Includes exclusive rights to a library of undisclosed monoclonal antibodies and research tools
- Companion diagnostics under development for patient selection